Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David J Back

Showing results (41-50 of 99) with videos related to

Pageof 10
Sort By:
The Journal of Antimicrobial Chemotherapy|September 28, 2014
Effect of intermittent rifampicin on the pharmacokinetics and safety of raltegravirHelen E Reynolds, Ales Chrdle, Deirdre Egan, et al.
Journal of Virology|October 14, 2004
Functional correlation of P-glycoprotein expression and genotype with expression of the human immunodeficiency virus type 1 coreceptor CXCR4Andrew Owen, Becky Chandler, Patrick G Bray, et al.
Tuberculosis (Edinburgh, Scotland)|January 30, 2007
Differential drug susceptibility of intracellular and extracellular tuberculosis, and the impact of P-glycoproteinRuben C Hartkoorn, Becky Chandler, Andrew Owen, et al.
Clinical Pharmacokinetics|December 20, 2014
Physiologically Based Pharmacokinetic Modelling to Inform Development of Intramuscular Long-Acting Nanoformulations for HIVRajith K R Rajoli, David J Back, Steve Rannard, et al.
Therapeutic Drug Monitoring|September 28, 2017
Comparison of Dried Blood Spots Versus Conventional Plasma Collection for the Characterization of Efavirenz Pharmacokinetics in a Large-Scale Global Clinical Trial-The ENCORE1 StudyAlieu B Amara, Laura J Else, Dianne Carey, et al.
Clinical Pharmacokinetics|May 23, 2019
Viral Hepatitis C Therapy: Pharmacokinetic and Pharmacodynamic Considerations: A 2019 UpdateElise J Smolders, Anouk M E Jansen, Peter G J Ter Horst, et al.
AIDS (London, England)|August 26, 2010
Darunavir concentrations exceed the protein-corrected EC₅₀ for wild-type HIV in the semen of HIV-1-infected menStephen Taylor, Ashini N Jayasuriya, Amanda Berry, et al.
Antiviral Therapy|August 24, 2007
Effect of transporter modulation on the emergence of nelfinavir resistance in vitroBecky Chandler, Maria Detsika, Andrew Owen, et al.
Bioanalysis|August 28, 2014
Quantification of rilpivirine in human plasma, cervicovaginal fluid, rectal fluid and genital/rectal mucosal tissues using liquid chromatography-tandem mass spectrometryLaura J Else, John Tjia, Akil Jackson, et al.
AIDS (London, England)|September 16, 2015
Effect of nondisclosure of HIV status in sexual health clinics on unlinked anonymous HIV prevalence estimates in England, 2005-2009Emma J Savage, Catherine M Lowndes, Ann K Sullivan, et al.
Pageof 10

Showing results (41-50 of 99) with videos related to

Sort By:
Pageof 10
The Journal of Antimicrobial Chemotherapy|September 28, 2014
Effect of intermittent rifampicin on the pharmacokinetics and safety of raltegravirHelen E Reynolds, Ales Chrdle, Deirdre Egan, et al.
Journal of Virology|October 14, 2004
Functional correlation of P-glycoprotein expression and genotype with expression of the human immunodeficiency virus type 1 coreceptor CXCR4Andrew Owen, Becky Chandler, Patrick G Bray, et al.
Tuberculosis (Edinburgh, Scotland)|January 30, 2007
Differential drug susceptibility of intracellular and extracellular tuberculosis, and the impact of P-glycoproteinRuben C Hartkoorn, Becky Chandler, Andrew Owen, et al.
Clinical Pharmacokinetics|December 20, 2014
Physiologically Based Pharmacokinetic Modelling to Inform Development of Intramuscular Long-Acting Nanoformulations for HIVRajith K R Rajoli, David J Back, Steve Rannard, et al.
Therapeutic Drug Monitoring|September 28, 2017
Comparison of Dried Blood Spots Versus Conventional Plasma Collection for the Characterization of Efavirenz Pharmacokinetics in a Large-Scale Global Clinical Trial-The ENCORE1 StudyAlieu B Amara, Laura J Else, Dianne Carey, et al.
Clinical Pharmacokinetics|May 23, 2019
Viral Hepatitis C Therapy: Pharmacokinetic and Pharmacodynamic Considerations: A 2019 UpdateElise J Smolders, Anouk M E Jansen, Peter G J Ter Horst, et al.
AIDS (London, England)|August 26, 2010
Darunavir concentrations exceed the protein-corrected EC₅₀ for wild-type HIV in the semen of HIV-1-infected menStephen Taylor, Ashini N Jayasuriya, Amanda Berry, et al.
Antiviral Therapy|August 24, 2007
Effect of transporter modulation on the emergence of nelfinavir resistance in vitroBecky Chandler, Maria Detsika, Andrew Owen, et al.
Bioanalysis|August 28, 2014
Quantification of rilpivirine in human plasma, cervicovaginal fluid, rectal fluid and genital/rectal mucosal tissues using liquid chromatography-tandem mass spectrometryLaura J Else, John Tjia, Akil Jackson, et al.
AIDS (London, England)|September 16, 2015
Effect of nondisclosure of HIV status in sexual health clinics on unlinked anonymous HIV prevalence estimates in England, 2005-2009Emma J Savage, Catherine M Lowndes, Ann K Sullivan, et al.
Pageof 10